Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org

February 2010

 



Home
Biopharmas Need Investment and Investors Need Clarity
Rib-X Founder Steitz Repeats Nobel Lecture
Rib-X, HistoRx, Affomix Draw 4Q Venture Capital
Long Wharf Hosts Forum on Alzheimer's Disease
Study Highlights CT Biotechs' Emphasis on Orphan Drugs
Study Shows CI Investments Grow CT Economy
Medal of Technology Nominations Now Open
Connecticut Stem Cell Research Roundup
CURE Member News Digest

Study Highlights CT Biotechs' Emphasis on Orphan Drugs

Several pharmaceutical companies with operations in Connecticut are focusing more on research into treatments for rare diseases, according to a study released by the Tufts Center for the Study of Drug Development.

The study mentions Pfizer, with R&D headquarters in New London and Groton, Alexion Pharmaceuticals in Cheshire, and Bristol-Myers Squibb, with operations in Wallingford, as among those receiving orphan-drug status for various treatments during the study period.

In the U.S., a product can be designated an orphan drug if it is meant to treat an illness that affects fewer than 200,000 people. In Europe, it goes to drugs for diseases affecting five out of every 10,000 people.

Since the Orphan Drug Act of 1983 was signed into law in the U.S. more than 2,000 products in development have been designated as orphan drugs, while the Food and Drug Administration has granted market approval to 350 drugs and biologicals.

Click here for more from the Tufts Center for the Study of Drug Development.

Click here for a related Hartford Business Journal article.

 

 

 
 
Copyright 2010 © Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
Click here for Archive of back issues.
Newsletter developed and edited by HarveyMalis Communications LLC, Guilford, Conn.

Managing Your Subscriptions
Click on the "Manage your subscription" link below and then on "Edit Your Profile." To subscribe to a publication, type a "y" in the box to the right of the publication name. To unsubscribe, leave the box blank.